Irinotecan Sun (Irinotecan Hydrochloride Trihydrate)

Irinotecan Sun is employed in the management of colorectal cancer and related disease stages.

• Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens.
• Colorectal adenocarcinoma: enhances tumor response rates as part of standard treatment protocols.
• Advanced colorectal cancer: provides disease control in patients who have progressed on prior therapies.

• Irinotecan is a prodrug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of DNA replication, and ultimately cancer cell death.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Diarrhea: often delayed and may be severe.
• Nausea and vomiting: typical chemotherapy‑related symptoms.
• Alopecia: hair loss during treatment cycles.
• Fatigue: generalized tiredness affecting daily activities.
• Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Severe (grade 3‑4) diarrhea: can lead to dehydration and electrolyte imbalance.
• Cholinergic syndrome: sweating, lacrimation, and bradycardia.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Bone marrow suppression: pancytopenia affecting multiple blood cell lines.

Prior to initiating Irinotecan therapy, several safety considerations are recommended.

• Monitor blood counts: perform regular CBC to detect neutropenia and anemia.
• Assess liver function: adjust dosing in patients with hepatic impairment.
• Evaluate renal function: consider dose modification for severe renal insufficiency.
• Review concomitant medications: avoid strong CYP3A4 or UGT1A1 inhibitors.
• Patient education: instruct on early signs of diarrhea and infection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure.
• UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia.
• Concurrent use with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely)

• Myelosuppressive agents (e.g., carboplatin): enhance bone‑marrow suppression.
• Anticholinergic drugs (e.g., atropine): may mask cholinergic syndrome.
• Warfarin: monitor INR as irinotecan can affect coagulation parameters.